The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global autoimmune disease diagnosis market reached a value of US$ 4.4 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.1% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
An autoimmune disease refers to a condition wherein the immune system attacks and destroys healthy cells, tissues, and organs of the body. In the longer run, it can also lead to abnormal growth of an organ and changes in organ function. Currently, more than 80 different autoimmune disorders have been identified by scientists, out of which Systemic Lupus Erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes, are the most common. Depending on the disorder, the doctor uses a combination of methods, which include a physical examination, medical history, blood tests, biopsy, and X-rays, to provide an effective diagnosis. They prescribe anti-inflammatory and immunosuppressant drugs, physical therapy, surgery, and injections, to control the overactive immune response and provide relief from symptoms.
Owing to the rising prevalence of autoimmune diseases, healthcare professionals around the world are focusing on the adoption of advanced technologies to conduct multiple tests with faster and more precise results. Apart from this, a large number of research and diagnostics institutes are undertaking public awareness campaigns to educate individuals about autoimmune diseases and their possible treatments and diagnosis, which is positively influencing the market growth. Furthermore, several governing authorities, along with non-governing organizations, are funding various programs to develop novel therapeutics. For instance, the AMP RA/SLE Program, launched by the Accelerating Medicines Partnership (AMP), is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA) and multiple non-profit organizations. The program aims to identify relevant drug targets for the treatment of autoimmune diseases.
Breakup by Product Type:
Breakup by Disease Type:
Breakup by Test Type:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Aesku.Diagnostics GmbH & Co. KG, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA (Institut Mérieux), Bio-Rad Laboratories Inc., Euroimmun AG (PerkinElmer Inc.), Hemagen Diagnostics Inc., Inova Diagnostics Inc. (Werfen Group S.A.), Myriad Genetics Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens AG), SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech, etc.
The global autoimmune disease diagnosis market was valued at US$ 4.4 Billion in 2020.
Sudden outbreak of the COVID-19 pandemic had led to the postponement of numerous elective diagnosis procedures, including blood tests, biopsy, X-rays, physical therapy, etc., for reducing the risk of coronavirus infection upon interaction with healthcare professionals or equipment.
We expect the global autoimmune disease diagnosis market to exhibit a CAGR of 8.10% during 2021-2026.
The rising adoption of numerous advanced technologies to conduct multiple tests simultaneously with faster and accurate results is currently driving the global autoimmune disease diagnosis market.
Based on the product type, the market has been bifurcated into consumables and assay kits, and instruments. Currently, consumables and assay kits hold the majority of the total market share.
Based on the disease type, the market can be divided into systemic autoimmune disease and localized autoimmune disease. Amongst these, localized autoimmune disease currently accounts for the majority of the total market share.
Based on the test type, the market has been segmented into routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and others. Currently, routine laboratory tests exhibit a clear dominance in the market.
On a regional level, the market has been segmented into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where Europe currently dominates the global market.
Some of the major players in the global autoimmune disease diagnosis market include Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMérieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., and Trinity Biotech plc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at